Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

por Shah, Manish A, Cunningham, David, Metges, Jean-Philippe, Van Cutsem, Eric, Wainberg, Zev, Elboudwarej, Emon, Lin, Kai-Wen, Turner, Scott, Zavodovskaya, Marianna, Inzunza, David, Liu, Jinfeng, Patterson, Scott D, Zhou, Jingzhu, He, Jing, Thai, Dung, Bhargava, Pankaj, Brachmann, Carrie Baker, Cantenacci, Daniel V T
Publicado 2021